NF-κB subunits RelA and c-Rel selectively control CD4+ T cell function in multiple sclerosis and cancer
Journal of Experimental Medicine · 03.06.2024 · 221 (6)
DOI: 10.1084/jem.20231348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 02.04.2024. Verfasst von Guilhem Lalle und 26 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Center of Lyon, Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, UMR INSERM 1052, CNRS 5286, Université Claude Bernar…. Hauptthemen laut MEDLINE: Multiple Sclerosis, Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0). Gefördert von: Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Labex DEVweCAN.
Abstract (Originalsprache)
The outcome of cancer and autoimmunity is often dictated by the effector functions of CD4+ conventional T cells (Tconv). Although activation of the NF-κB signaling pathway has long been implicated in Tconv biology, the cell-autonomous roles of the separate NF-κB transcription-factor subunits are unknown. Here, we dissected the contributions of the canonical NF-κB subunits RelA and c-Rel to Tconv function. RelA, rather than c-Rel, regulated Tconv activation and cytokine production at steady-state and was required for polarization toward the TH17 lineage in vitro. Accordingly, RelA-deficient mice were fully protected against neuroinflammation in a model of multiple sclerosis due to defective transition to a pathogenic TH17 gene-expression program. Conversely, Tconv-restricted ablation of c-Rel impaired their function in the microenvironment of transplanted tumors, resulting in enhanced cancer burden. Moreover, Tconv required c-Rel for the response to PD-1-blockade therapy. Our data reveal distinct roles for canonical NF-κB subunits in different disease contexts, paving the way for subunit-targeted immunotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cancer Research Center of Lyon, Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1 , Lyon, France.
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), UMR INSERM 1291, CNRS 5051, Université Toulouse III , Toulouse, France.
- Cancer Research Center of Lyon, Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, Gilles Thomas Bioinformatics Platform, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1 , Lyon, France.
- Biology Department, Ecole Normale Supérieure of Lyon, Lyon, France.
- Laboratory of Biology and Modelling of the Cell, Ecole Normale Supérieure of Lyon, CNRS UMR 5239, INSERM U1293 , Lyon, France.
- Department of Microbiology and Immunology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
ORCID-Profile: Guilhem Lalle, Raphaëlle Lautraite, Khaled Bouherrou, Maud Plaschka, Aurora Pignata, Allison Voisin, Julie Twardowski, Marlène Perrin-Niquet, Pierre Stéphan, Sarah Durget, Laurie Tonon, Maude Ardin, Cyril Degletagne, Alain Viari, Laurence Belgarbi Dutron, Nathalie Davoust, Thomas S Postler, Jingyao Zhao, Christophe Caux, Julie Caramel, Stéphane Dalle, Philippe A Cassier, Ulf Klein, Marc Schmidt-Supprian, Roland Liblau, Sankar Ghosh, Yenkel Grinberg-Bleyer
Förderung
- Centre National de la Recherche Scientifique
- Institut National de la Santé et de la Recherche Médicale
- Labex DEVweCAN
- ARSEP Foundation
- ARC Foundation
- Fondation pour la Recherche Médicale
Zitieren
APA
Lalle, G., Lautraite, R., Bouherrou, K., Plaschka, M., Pignata, A., Voisin, A., Twardowski, J., Perrin-Niquet, M., Stéphan, P., Durget, S., Tonon, L., Ardin, M., Degletagne, C., Viari, A., Belgarbi Dutron, L., Davoust, N., Postler, T. S., Zhao, J., Caux, C., …, & Grinberg-Bleyer, Y. (2024). NF-κB subunits RelA and c-Rel selectively control CD4+ T cell function in multiple sclerosis and cancer. Journal of Experimental Medicine, 221(6). https://doi.org/10.1084/jem.20231348
Vancouver
Lalle G, Lautraite R, Bouherrou K, Plaschka M, Pignata A, Voisin A, et al. NF-κB subunits RelA and c-Rel selectively control CD4+ T cell function in multiple sclerosis and cancer. Journal of Experimental Medicine. 2024;221(6). doi:10.1084/jem.20231348
BibTeX
@article{Lalle2024,
author = {Lalle, Guilhem and Lautraite, Raphaëlle and Bouherrou, Khaled and Plaschka, Maud and Pignata, Aurora and Voisin, Allison and Twardowski, Julie and Perrin-Niquet, Marlène and Stéphan, Pierre and Durget, Sarah and Tonon, Laurie and Ardin, Maude and Degletagne, Cyril and Viari, Alain and Belgarbi Dutron, Laurence and Davoust, Nathalie and Postler, Thomas S and Zhao, Jingyao and Caux, Christophe and Caramel, Julie and Dalle, Stéphane and Cassier, Philippe A and Klein, Ulf and Schmidt-Supprian, Marc and Liblau, Roland and Ghosh, Sankar and Grinberg-Bleyer, Yenkel},
title = {NF-κB subunits RelA and c-Rel selectively control CD4+ T cell function in multiple sclerosis and cancer},
journal = {Journal of Experimental Medicine},
year = {2024},
volume = {221},
number = {6},
doi = {10.1084/jem.20231348}
}
EUVIMED